Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Genmab is a promising investment opportunity with a positive outlook due to its strong partnership with Johnson & Johnson for DARZALEX, a leading product in the multiple myeloma market. The company also has a diverse pipeline with promising candidates targeting different oncologic indications, which could drive future growth. However, risks include potential challenges in obtaining label extensions and competition from other agents in clinical testing.

Bears say

Genmab is showing signs of strong financial performance with net earnings exceeding expectations and a solid cash balance of ~$2.9B. However, the negative outlook is due to concerns about the company's future pipeline and potential market saturation for its leading product, DARZALEX, which accounted for a majority of the company's revenue in 2025. Additionally, increased competition in the biotech sector and potential for clinical trial setbacks could impact the company's profitability and valuation.

GMAB has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 7 analysts, GMAB has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.